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Rezumat
Polimorfi smul NAT2 (arilaminice N-acetil 2), determinant-cheie al variaţiilor individuale în capacitatea de acetilare, 
este suspectat de modifi carea risculului de tumori maligne. Ca fumul de tutun şi alte substanţe inhalate, conţine o varietate 
de substraturi NAT2. Relaţia dintre fenotipul NAT2 şi cancerul pulmonar este obiectul de cercetare intensivă al diferitor 
studii de caz-control, ale căror rezultate au produs controverse.
Summary
NAT2 (arylamine N-acetyltransferase 2) polymorphism, being a key determinant of individual variations in acetylation 
capacity, is suspected to modify the risk of carcinogen-related malignancies. As tobacco smoke and other inhaled hazards 
contain a variety of NAT2 substrates, the relationship between NAT2 phenotype and lung cancer (LC) risk has been a subject 
of intensive research, however different case-control studies produced controversial data. In the present report, we employed 
a novel ,,comparison of extremes” approach, i.e., we compared the distribution of NAT2 genotypes in lung cancer patients 
(LC, n = 178) not only to the population controls (healthy donors (HD), n = 364), but also to the subjects with a putative 
cancer-resistant constitution (elderly tumor-free smokers and non-smokers (ED), n = 351). Frequencies of homozygous 
rapid, heterozygous rapid and slow acetylators were 6%, 39% and 56% in LC, 8%, 32% and 60% in HD, and 6%, 35% and 
59% in ED, respectively). Comparison of the NAT2 genotype frequencies between affected and non-affected individuals 
did not reveal any statistical deviations, irrespectively of smoking history, gender, age, or histological type of LC. Adjusted 
odds ratio for rapid vs. slow acetylators was 1.12 (95% confi dence intervals (CI): 0.73 - 1.74) comparing LC vs. HD, and 
1.10 (95% CI: 0.74 - 1.62) comparing LC vs. ED. Similar distribution of NAT2 acetylator genotypes both in tumor-prone 
and in tumor-resistant groups suggests that, despite the presence of NAT2 carcinogenic substrates in tobacco smoke. NAT2 
polymorphism does not play a noticeable role in lung cancer susceptibility.
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Introduction. Lung cancer (LC) is the leading cause of tumor-related mortality in the world. Smoking 
plays an utmost role in the etiology of this disease, being responsible for more than 85% of LC cases. Another 
important factor contributing to LC risk is the genetic background of the individual. Although LC is not a 
part of highly penetrant single-gene cancer syndromes, normal genetic variations within humans are likely to 
play an essential role in LC susceptibility. For example, unfavorable combinations of single nucleotide gene 
polymorphisms (SNPs) of genes involved in the metabolism of tobacco smoke carcinogens have been shown 
to slightly modify the risk of LC. In addition, overrepresentation of certain DNA repair gene SNPs in LC 
patients has been described in the literature [1-3]. 
Another class of polymorphic candidates, which deserves particular attention, consists of genes 
participating in apoptotic response to DNA damage. It has been proposed that cell failure to execute suicide 
upon non-repairable alteration of DNA structure may result in accumulation of clones, which contain cancer-
driving mutations. Several phenotypic studies demonstrated an association between low apoptotic capacity 
and elevated cancer risk, but negative fi ndings have been reported as well. There is also a number of reports 
describing distinct distribution of apoptotic SNPs in LC cancer patients, but systematic studies in this fi eld 
remain to be done [4-12].
Search for low-penetrance gene-disease interactions is complicated due to weakness of the expected 
associations. Current demands aimed to improve the effi ciency of molecular epidemiological research are 
focused on the drastic increase of the study size as well as perfect adjustment of cases and controls for all 
possible confounding parameters. However, this approach certainly has its limits; at the moment, available 
DNA collections and genotyping technologies allow to obtain truly defi nite results for no more than a few 
dozens or hundreds of SNPs. Therefore, alternative strategies for robust sorting of polymorphic candidates 
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are warranted. We have introduced earlier a non-traditional design for molecular epidemiological study, which 
is called ,,comparison of extremes” [13-16]. Instead of performing SNP testing in random sets of cases and 
controls, we suggested to select for the initial SNP assessment only those subjects, who are characterized by 
particularly demonstrative characteristics of cancer predisposition or tolerance. For example, at-risk genotypes 
are likely to accumulate in those patients who acquired LC disease at a relatively young age and/or experienced 
relatively low carcinogen exposure (e.g., in LC non-smokers or light smokers). In contrast, elderly tumor-free 
smokers appear to represent an example of LC tolerance and thus may serve as a valuable ,,supercontrol” 
for LC association studies. We attempted to use these ,,extreme” groups of cases and controls for the rapid 
assessment of the role of apoptotic gene SNPs in LC predisposition.
Materials and methods
Patients and controls.Case-control comparison of SNP frequencies was done by 2-stage approach. Initial 
analysis of candidate SNPs was intended to compare subjects with highly demonstrative characteristics of 
LC susceptibility or tolerance.  Group of ,,extreme” LC susceptibility (n = 111) was selected from the total 
collection of 351 LC samples, and included 17 non-smokers as well as 94 patients characterized by relatively 
modest smoking history (mean: 30 pack/years; range: 10 - 40) and young age at the disease onset (mean: 54 
years; range: 32 - 64). ,,Supercontrol” group of elderly tumor-free heavy smokers was selected from a total 
collection of 2791 non-affected subjects based on the highest cigarette consumption and age threshold 75 years, 
and contained 110 individuals (mean age: 79 years; age range: 75 - 89; mean smoking exposure: 55 pack/years; 
range: 30 - 126). SNPs demonstrating promising trends upon ,,comparison of extremes” were subjected to the 
traditional case-control comparison. 351 LC (mean age: 61 year; range: 30 - 84) included 303 smokers (mean 
pack/years: 41; range: 10 - 150) and 48 non-smokers. Control group (n = 538; mean age: 61 years; range: 32 
- 84) did not include subjects, who were genotyped at the “comparison of extremes” stage, and consisted of 
474 smokers (mean pack/years: 22; range: 1 - 111) and 64 non-smokers. Peripheral blood leucocytes were the 
source of DNA for all the above groups. For the genotyping of Casp8 His302Asp polymorphism, additional 
127 DNA samples obtained from archival normal tissues of LC non-smokers (mean age: 61 year; range: 16 - 
82) were utilized. All DNA samples described above were obtained from residents of St.-Petersburg (Russia). 
In addition, we utilized an independent set of cases and controls, who were recruited in another republic of 
former Soviet Union, Moldova.  This collection consisted of 296 LC (mean age: 58 years; range: 22 – 79; 232 
smokers (mean pack/years: 43; range: 3 - 132) and 64 non-smokers) and 295 non-affected subjects (mean age: 
56 years; range: 22 - 80; 207 smokers (mean pack/years: 25; range: 3 - 130) and 88 non-smokers).
DNA isolation and SNP genotyping. Genomic DNA was extracted from peripheral blood leucocytes by 
modifi ed salt–chloroform extraction [17]. Briefl y, 3 ml of blood were diluted by water up to 10 ml in order 
to achieve hemolysis, mononuclear cells were pelleted by gentle centrufugation and resuspended in 1 ml of 
TE solution (10 mM Tris-HCl (pH 8.3), 1 mM EDTA). Plasma membranes were destroyed by the addition of 
Triton X-100 up to 1%, and the samples were centrifuged again to pellet the nuclei. The pellet was resuspended 
in the TE solution and incubated with proteinase K (100 μg/ml) at 60°C overnight. Proteins were precipitated 
by the addition of NaCl up to 1.5 M, and the lysates were subjected to chlorophorm extraction.  Then equal 
volume of isopropanol was added, DNA was picked up by rotating glass stick, washed in 70% ethanol and 
dissolved in the TE buffer. 
Archival samples were processed as described in [18]. 10 μm archival sections were deparaffi nized in 
xylene and boiled for 5 min. in the lysis buffer (10 mM Tris-HCl (pH 8.3); 1 mM EDTA; 0.5% NP-40, 0.5% 
Tween 20). Proteinase K was added up to 500 μg/ml, and the samples were incubated at 60°C overnight. 
Finally, the proteinase K was inactivated by boiling for 5 min in the presence of Chelex-100, and the obtained 
lysates were used for PCR amplifi cation.  
The list of 37 coding non-synonymous SNPs in apoptotic genes was adopted from our previous publication 
[7]. SNPs were genotyped by allele-specifi c polymerase chain reaction (AS-PCR) [19]. Sequences of the PCR 
primers are presented in the Table 1. PCR reactions were carried in a 20 μl fi nal volume using iCycler iQ Real 
Time Detection System (Bio-Rad). Each tube contained 50-100 ng of genomic DNA, 1 μM of each primer, 
200 μM deoxynucleotide triphosphates, 1x PCR buffer, 2,5 mM MgCl2, 0.5
x SYBR Green I, and 1 unit of hot-
start Taq polymerase (,,Thermostar”, Helicon, Moscow). Taq polymerase was activated by 10 min. heating at 
95°C. 45 PCR reaction cycles included denaturation at 95°C for 20 s, annealing at 55°C - 67°C for 35 s (see 
Table 1), and synthesis at 72°C for 35 s.  The reliability of allele discrimination was systematically controlled 
by gel-electrophoresis of PCR fragments.
 Statistical analysis. Deviation of genotypes distribution from Hardy-Weinberg equilibrium (HWE) in 
control subjects was assessed using the chi-square test with one degree of freedom. Primary comparisons 
of genotype frequencies in cases versus controls were performed by the trend test (p-trend) (one degree of 
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freedom) and the heterogeneity test (p-het) (two degrees of freedom). The signifi cance of potential at-risk 
genotypes was assessed by calculating odds ratios (OR) with 95% confi dence intervals (CI).
Results. We have considered for the study 37 coding non-synonymous SNPs in apoptotic genes, which 
have been validated by populational frequency (SNP NCBI database (http://www.ncbi.nlm.nih.gov/SNP/) and 
listed in our earlier publication [7]. p53 Arg72Pro polymorphism was excluded from the analysis, because its 
involvement in LC predisposition has been explicitly tested in previous reports [20]. Successful genotyping 
assays have been developed for 33 SNPs; we were not successful in analyzing the remaining 3 polymorphisms 
(Casp1 Gln37Lys, DR3 Gly159Asp, and DR5 Leu32Pro), despite the repetitive attempts to optimize primer 
sequences and PCR conditions. Another 14 SNPs (Bcl2 Thr43Ala, Bik Pro148Leu, Bcl-x Gly160Val, Casp5 
Leu13Phe, Casp5 His152Arg, Casp5 Leu201Val, Casp6 Glu34Ala, Casp6 Lys35Glu, Fas Thr16Ala, Fas 
Ile122Thr, DR4 Ile33Thr, DR4 His297Asn, TNFR1 Leu75Pro, TRAIL Glu47Asp) demonstrated null frequency 
in our collection of DNA samples. 
Thus, comparison of allele distribution in groups with „extreme” degrees of cancer susceptibility 
versus tolerance was performed for 19 SNPs. Because the involved categories of subjects which appear to 
have indeed opposite characteristics of LC risk, we assumed that truly meaningful LC-predisposing alleles 
would demonstrate clearly detectable odds ratios (ORs). If we consider OR = 3 as a reasonable threshold 
for the comparison of „extremes” [16, 21], and rely on a p value = 0.1, the study would have 99% power to 
detect at-risk allele with populational frequency 30%, and 90% power for the allele occurring in 10% of the 
subjects. 4 out of 19 tested SNPs (Casp5 Ala90Thr, Casp5 Val318Leu, Casp8 His302Asp, DR4 Lys441Arg) 
demonstrated p < 0.1 (Table 2). However, Casp5 Ala90Thr polymorphism was excluded from further study 
because the difference in its distribution between cases and controls was caused purely by the alteration of 
the Hardy-Weinberg equilibrium (depletion of heterozygotes) in the group of elderly tumor-free smokers; 
furthermore, we considered our data sets obtained for other categories of subjects (breast cancer patients and 
female controls; data not shown), and concluded that the Casp5 Ala90Thr variation is an unlikely contributor 
in LC susceptibility. Subgroup analysis of LC cases according to smoking status and tumor histological type 
did not reveal additional promising SNPs (data not shown).
Based on the presented above results of the preliminary screening, Leu/Leu-homozygotes for Casp5 Val318Leu 
(OR = 2.41 (95% CI: 1.02 – 5.70)), His-carriers for Casp8 His302Asp (OR = 2.26 (95% CI: 1.18 - 4.3)) and Arg-
carriers for DR4 Lys441Arg (OR = 1.89 (95% CI: 1.06 – 3.38)) polymorphisms were considered as a candidate 
LC-predisposing genotypes and therefore subjected to the extended analysis. For the LC group, we added to the 
genotyping set the remaining 240 samples from our total collection of 351 non-selected LC cases, while for the 
control group we were able to compose an independent set of 538 non-affected subjects. In addition, we involved 
an additional collection from Moldova consisting of 296 LC patients and 295 controls. The study had 80% power at 
nominal signifi cance level 0.05 to detect Mantel-Haenszel OR = 1.48, 1.41, and 1.38, respectively, for the mentioned 
above at-risk genotypes.  The results of the case-control comparison are presented in Table 3. Interestingly, all three 
suspected at-risk genotypes demonstrated OR values above 1 both in Russian and Modovian case-controls series. 
However, none of statistical tests passed the threshold for signifi cance (Table 4).  
The subgroup analysis for LC histological type, gender, age and other disease variables failed to reveal 
additional associations. However, consideration of smoking status provided suggestive evidence for the 
association between Casp8 genotype and LC cancer risk in non-smokers. The frequency of His-carriers in 
the latter category of Russian patients (19/48 (40%)) signifi cantly exceeded the one in the controls (118/538 
(22%), p = 0.006); furthermore, similar but statistically non-signifi cant trend was noticed in Moldovian subjects 
(16/64 (25%) versus 63/21 (p = 0.52)). Recent evidence indicates that LC in non-smokers may represent 
entirely distinct disease; therefore one could speculate that this type of neoplasia has authentic determinants of 
genetic predisposition [22, 23]. In order to validate the obtained correlation, we invoked additional 127 DNA 
samples from Russian LC non-smokers by utilizing normal tissues from archival paraffi n-embedded samples. 
The frequency of His-carriers in newly genotyped LC non-smokers was identical to one observed in controls, 
i.e. 22% (28/127), that argued against the above association. 
Discussion. This investigation was aimed to analyze the association between coding SNPs in apoptotic 
genes and LC predisposition. The preliminary sorting of SNP candidates was done by comparing subjects with 
„extreme” degrees of LC susceptibility versus tolerance. The group of LC cases was composed of patients 
selected on the basis of either absence of smoking history, or light smoking exposure coupled with the young 
age at the disease onset. It is expected, that truly at-risk alleles would have an evident overrepresentation 
in this group of patients, although the exact extent of the effect is diffi cult to estimate. Research on breast 
cancer (BC) genetic susceptibility has demonstrated that the probability to detect BC-predisposing variant 
increases several-fold in properly selected categories of patients [21]. However, similar calculations for the 
219
frequencies of LC-associated alleles in „high-risk” versus non-selected categories of lung cancer patients are 
more complicated, due to shortage of well-proven gene-disease interactions and corresponding case-control 
data sets. On the other hand, LC studies have an unique opportunity of enrichment of control category of 
subjects. Current evidence indicates that smokers have drastically decreased chances to achieve a reasonably 
old age while remaining cancer-free [24]. Again, the exact prediction of the degree of the effect is complicated 
for the time being, due to the impact of concurrent smoking-related illnesses and geographic variations in 
life expectancy. Nevertheless, one would certainly expect an evident depletion of LC-predisposing at-risk 
genotypes in a group of elderly tumor-free heavy smokers. Given the above assumptions, OR = 3 and p < 
0.1 may look as an appropriate threshold at the ,,comparison of extremes” stage, and the present study was 
suffi ciently powered to detect promising SNP candidates for extended testing. 
Three SNPs were pinpointed by the ,,comparison of extremes” approach (Casp5 Val318Leu, Casp8 
His302Asp, and DR4 Lys441Arg). Although none of these associations passed the validation by extended 
case-control analysis, all candidate at-risk genotypes consistently demonstrated odds ratios above 1 both in 
Russian and in Moldovian case-control series (Table 4). The biological function of the caspase-5 protein is 
poorly understood. Caspase-5 is believed to play a role in various aspects of infl ammation [25]; in addition, 
Casp5 gene was repeatedly shown to be a target for mutation in a subset of human cancers [26].  In contrast, 
the role of caspase-8 in the programmed cell death has been studied with signifi cant level of comprehension. 
Interestingly, His allele carriers for Casp8 His302Asp were reported to have a reduced risk of breast cancer 
[27]. DR4 mediates ligand-induced apoptosis; some data indicate that DR4 may be involved in predisposition 
to tumor development [4, 28].
  If we assume that these polymorphisms indeed predispose to LC with OR = 1.2 (Table 4), the 
validation of this association will require the analysis of 3000 LC cases and 3000 controls. The collections of 
this size are not yet available in individual cancer institutes, but can be utilized in collaborative multicenter 
studies [29]. Aside the sample size, another potential limitation of the study is related to the mode of SNP 
selection. Our investigation relied on the list of coding non-synonymous SNPs in apoptotic genes, which was 
composed in 2005 [7]. The number of identifi ed SNPs continues to grow on a regular basis, and there are some 
interesting candidates which could not be considered when the above study was planned. For example, NCBI 
SNP database (http://www.ncbi.nlm.nih.gov/SNP/) contains some new validated coding polymorphisms, 
which are characterized by relatively high frequency (> 5%) and therefore deserve attention at the fi rst hand 
(Boo Arg21Leu (rs2231292), Casp1 His15Arg (rs1042743), Casp7 Glu4Asp (rs11593766), Casp9 Arg176Gly 
(rs2308949), DcR2 Pro345Thr (rs34622674), DcR2 Ser310Leu (rs1133782), DR3 Gln23Arg (rs35771371), 
DR5 Val67Ala (rs1047266), DR5 Ala191Val (rs13265018), FasL Val266Leu (rs35178418), XIAP Phe133Ser 
(rs28382722)). Furthermore, while functional consequences of non-coding gene polymorphisms are less 
understood relative to coding SNPs, it is beyond the doubt that genotype-phenotype relationships are not 
limited to amino acid variations. Interestingly, recent advances in genome-wide analysis of cancer associated 
SNPs led to an identifi cation of several tagging at-risk polymorphisms, including some located in the vicinity 
to apoptotic genes, but no linked changes in amino acid sequence have been reported yet [10, 30]. Non-coding 
apoptotic gene SNP candidates have not been considered in the present report. Finally, this study did not 
consider the role of SNP combinations in determining the disease susceptibility. It is possible that certain SNPs 
modify cancer predisposition only within particular genetic context, however signifi cantly larger sample size 
and extensive subgroup analysis are required to reveal such gene-gene interactions. 
The existence of multiple cancer subtypes also complicates the search for disease predisposing SNPs. LC 
may serve as a particularly valuable example of this type of diffi culties. Although some investigations discussed 
specifi c features of lung cancer in non-smokers since a long time, this subtype of LC was rarely considered as 
a truly distinct disease. Recent clinical trials on epidermal growth factor receptor (EGFR) inhibitors (gefi tinib 
or erlotinib) led to an identifi cation of previously unknown intragenic mutations in the EGFR gene, which are 
associated with pronounced tumor response to the treatment. Interestingly, these mutations demonstrate strong 
preference to occur in non-smoking lung cancer patients, thus gefi tinib and erlotinib showed clearly superior 
therapeutic effi cacy for LC in non-smokers versus smokers. This unexpected clinical discovery attracted high 
level of attention to the comparison of molecular profi les of lung tumors in non-smokers versus smokers; there 
is some evidence that tobacco-unrelated LC may develop by entirely distinct mechanisms, and therefore be 
mediated by a separate group of risk factors [22, 23]. In our study, we deliberately limited the proportion of 
non-smokers in the ,,extreme” group of LC cases to the one observed in non-selected LC patients, therefore our 
approach to the initial sorting of SNPs looks fairly adequate relative to the current knowledge on LC subtypes. 
However, one cannot exclude the possibility that more profound LC categorization will be required in future 
molecular epidemiological studies. Within this context, one could make a parallel with the most studied cancer 
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type, i.e. breast cancer (BC). Recent studies indicate that this disease consists of several molecular variants, 
and, strikingly, estrogen-dependent BC appears to have distinct risk factors when compared to the hormone-
independent disease [30-32]. 
In conclusion, this study involved 2-stage design for the systematic analysis of coding non-synonymous 
SNPs in apoptotic genes. Three candidate at-risk genotypes (Leu/Leu-homozygotes for Casp5 Val318Leu 
polymorphism, His-carriers for Casp8 His302Asp polymorphism, and Arg-carriers for DR4 Lys441Arg 
polymorphism) were identifi ed while comparing groups with „extreme” degrees of LC susceptibility versus 
tolerance (early-onset light-smoking or non-smoking LC patients versus elderly tumor-free heavy smokers). In 
the validation study, all these candidate genotypes consistently demonstrated OR above 1 in two independent 
case-control series, however the associations did not achieve the level of statistical signifi cance. Taken together, 
the obtained data indicate that Casp5, Casp8 and DR4 gene polymorphisms may deserve consideration in 
large-scale case-control studies of LC risk modifi ers.  
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Table 1 
SNPs and primers for allele-specifi c PCR 
































































































































































,,Comparison of extremes”: distribution of apoptotic SNPs 
in subjects with highly demonstrative characteristics of LC predisposition versus tolerance 














AA 108 (97.3) 109 (99.1) 1
0.99 0.32 0.32AG 3 (2.7) 1 (0.9) 3.03 (0.31-29.6)




GG 102 (91.9) 101(91.8) 1
0.90 0.98 0.98CG 9 (8.1) 9 (8.2) 0.99 (0.38-2.60)




AA 29 (26.1) 34 (30.9) 1
0.11 0.07 0.58AG 61 (55.0) 44 (40.0) 1.63 (0.87-3.05)




GG 48 (43.2) 52 (47.3) 1
0.86 0.09 0.14CG 43 (38.7) 49 (44.5) 0.95 (0.54-1.68)




CC 57 (51.4) 57 (51.8) 1
0.99 0.32 0.62CG 50 (45.0) 44 (40.0) 1.14 (0.65-1.96)




GG 77 (69.4) 92 (83.6) 1
0.65 0.03 0.01CG 33 (29.7) 18 (16.4) 2.19 (1.44-4.19)




TT 40 (36.0) 38 (34.5) 1
0.96 0.51 0.44TC 57 (51.4) 52 (47.3) 1.04 (0.58-1.86)




GG 108 (97.3) 102 (92.7) 1
0.92 0.12 0.12AG 3 (2.7) 8 (7.3) 0.35 (0.09-1.37)




GG 39 (35.1) 37 (33.6) 1
0.99 0.75 0.57AG 56 (50.5) 53 (48.2) 1.00 (0.56-1.80)




TT 33 (29.7) 43 (39.1) 1
0.13 0.33 0.28AT 52 (46.8) 43 (39.1) 1.58 (0.85-2.89)




GG 27 (24.3) 32 (29.1) 1
0.94 0.37 0.99AG 64 (57.7) 53 (48.2) 1.43 (0.76-2.68)




GG 22 (19.8) 32 (29.1) 1
0.52 0.21 0.39CG 61 (55.0) 49 (44.5) 1.81 (0.94-3.51)





AA 81 (73.0) 87 (79.1) 1
0.86 0.56 0.29AC 27 (24.3) 21 (19.1) 1.38 (0.72-2.63)




AA 70 (63.1) 84 (76.4) 1
0.66 0.08 0.06AG 38 (34.2) 23 (20.9) 1.98 (1.08-3.64)




GG 101 (91.0) 106 (96.4) 1
0.98 0.10 0.10AG 10 (9.0) 4 (3.6) 2.62 (0.80-8.63)




AA 109 (98.2) 108 (98.2) 1
0.99 0.99 0.99AG 2 (1.8) 2 (1.8) 0.99 (0.14-7.16)




AA 101 (91.0) 100 (90.9) 1
0.89 0.98 0.98AG 10 (9.0) 10 (9.1) 0.99 (0.40-2.48)




GG 108 (97.3) 103 (93.6) 1
0.94 0.19 0.19AG 3 (2.7) 7 (6.4) 0.41 (0.10-1.62)





AA 6 (40.0) 55 (38.7) 1
0.18 0.79 0.68AC 7 (46.7) 58 (40.8) 1.11 (0.35-3.50)





A 53 (55.2) 70 (63.6) 1
- 0.22 0.22
C 43 (44.8) 40 (36.4) 1.42 (0.81-2.48)
Total 111 (100) 110 (100)
XIAP is located on X chromosome; therefore males have only one allele of this gene. For the analysis of 
XIAP Pro423Gln genotypes in females, additional 142 elderly non-affected females were examined as controls. 
Three genotypes demonstrated potential association with LC risk, i.e. Leu/Leu-homozygotes for Casp5 Val318Leu 
(OR = 2.47 (95% CI: 1.07 – 5.69), p = 0.03), His-carriers for Casp8 His302Asp (OR = 2.26 (95% CI: 1.18 - 4.31), 
p = 0.02), and Arg-carriers for DR4 Lys441Arg (OR = 1.89 (95% CI: 1.05 – 3.40), p = 0.03).
Table 3 
Validation study for the candidate SNPs




GG 137 (39.0) 221 (41.1) 103 (34.8) 107 (36.3)
CG 158 (45.0) 248 (46.1) 134 (45.3) 133 (45.1)




GG 263 (74.9) 420 (78.1) 226 (76.4) 232 (78.6)
CG 83 (23.6) 112 (20.8) 67 (22.6) 58 (19.7)




AA 250 (71.2) 399 (74.2) 210 (70.9) 222 (75.3)
AG 89 (25.4) 126 (23.4) 83 (28.0) 70 (23.7)
GG 12 (3.4) 13 (2.4) 3 (1.0) 3 (1.0)
Total 351 (100) 538 (100) 296 (100) 295 (100)
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Table 4 
Odds ratios and confi dence intervals for candidate at-risk genotypes
SNP OR (95% CI) and p values Mantel-Haenszel OR (95% CI) and p valuesRussia Moldova 
Casp5 Val318Leu ,
Leu/Leu-genotype 1.31 (0.87 - 1.98), p = 0.20 1.11 (0.71 - 1.76), p = 0.64 1.22 (0.90 - 1.65), p = 0.21
Casp8 His302Asp,
His-carriers 1.19 (0.87 - 1.63), p = 0.28 1.14 (0.78 - 1.68), p = 0.51 1.17 (0.92 - 1.50), p = 0.21
DR4  Lys441Arg,
Arg-carriers 1.16 (0.86 - 1.57), p = 0.34 1.24 (0.87 - 1.80), p = 0.24 1.19 (0.95 - 1.51), p = 0.14
Rezumat
Apoptoza joacă un rol important în eliminarea celulelor ADN-deteriorate, protejând astfel gazda de la dezvoltarea 
cancerului. Unele date indică faptul că variaţiile normale în secvenţa de gene apoptotic poate duce la capacitatea de apoptotic 
suboptimal şi, prin urmare, la creşterea riscului de cancer. Am testat 19 secvenţe de codifi care SNP apoptotic, în 2 etape 
studiu epidemiologic molecular. Pentru sortarea preliminară a candidaţilor SNP, am utlizat o ,,comparaţie a extremelor”.
Summary
Apoptosis plays a role in the elimination of DNA-damaged cells thus protecting the host from cancer development. 
Some data indicate that normal variations within the sequence of apoptotic genes may lead to suboptimal apoptotic capacity 
and therefore increased cancer risk. We tested 19 coding apoptotic gene SNPs in 2-stage molecular epidemiological 
study. For the preliminary sorting of SNP candidates, we employed a ,,comparison of extremes” approach, where 111 
patients with highly pronounced LC susceptibility (non-smokers or young-onset light smokers) were analyzed against 110 
subjects with the evidence for LC tolerance (elderly tumor-free heavy smokers). Three genotypes demonstrated possible 
association with LC risk (Leu/Leu-homozygotes for Casp5 Val318Leu versus other genotypes: OR = 2.47 (95% CI: 1.07 
– 5.69), p = 0.03; His-carriers for Casp8 His302Asp: OR = 2.26 (95% CI: 1.18 - 4.31), p = 0.02; Arg-carriers for DR4 
Lys441Arg: OR = 1.89 (95% CI: 1.05 – 3.40), p = 0.03), and therefore were selected for the validation. The extended study 
included 2 case-control series, namely subjects from Russia (351 LC cases and 538 controls) and Moldova (296 LC cases 
and 295 controls). Interestingly, all three candidate genotypes consistently demonstrated OR above 1 both in Russian and 
in Moldovian groups. Although the combined Mantel-Haenszel analysis yet failed to reach statistical signifi cance (OR = 
1.22 (95% CI: 0.90 - 1.65), p = 0.21; OR = 1.17 (95% CI: 0.92 - 1.50), p = 0.21; OR = 1.19 (95% CI: 0.95 - 1.51), p = 0.14, 
respectively), the obtained data indicate that Casp5, Casp8 and DR4 gene polymorphisms may deserve consideration in 
large-scale case-control studies of LC risk modifi ers.  
PARTICULARITĂŢI CLINICO-MORFOLOGICE ŞI IMUNOHISTOCHIMICE 
ALE SARCOMULUI KAPOSI
Diana Harştea, doctorandă, Iraida Iacovlev, dr. hab. în medicină, prof. univ., 
Anatolie Cernîi, dr. hab. în medicină, prof. univ.
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Sarcomul Kaposi este o tumoare de origine vasculară cu localizare muco-cutanată, cu manifestări clini-
co-morfologice foarte variabile, care deseori ridică probleme de diagnostic [1]. Această afecţiune tumorală se 
dezvoltă mai frecvent la persoanele în vârstă cu defi cienţă imună, deseori la pacienţii cu SIDA, transplant de 
organ, infecţie cu herpesvirusul uman tipul 8 (HHV 8) şi alte infecţii virale [2]. Tot mai mult se presupune că 
sarcomul Kaposi este un neoplasm al endoteliului limfovascular infectat cu HHV 8 care reprogramează genele 
responsabile de reglarea dezvoltării vaselor limfatice  [3]. Imunohistochimic, în celulele fusiforme neoplazice, 
pozitive la markerul limfovascular D2-40, din sarcomul Kaposi se detectează antigenul nuclear latent (LNA-
1), asociat la HHV 8  [4].   
Conform manifestărilor clinice, sunt descrise  [2] patru tipuri principale de sarcom Kaposi: 1) tipul 
clasic, deosebit de răspândit în Europa, la persoanele în vârstă, care se caracterizează prin leziuni cutanate 
ale extremităţilor cu evoluţie lentă; 2) tipul african endemic, care afectează copiii şi persoanele tinere, în care 
leziunile cutanate pot fi  asociate cu limfadenopatii generalizate şi progresare rapidă a bolii; 3) tipul imunosu-
presiv, cel iatrogenic, apărut la pacienţii cu transplant de organ, manifestat prin leziuni cutanate localizate sau 
diseminate şi printr-o evoluţie lentă sau progresivă în circa 30% cazuri; 4) tipul epidemic, instalat la bolnavii 
de SIDA, caracterizat prin leziuni muco-cutanate şi viscerale, deseori, cu o evoluţie fulminantă.
